NCT00925223|UnknownDMC
Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients
Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients
Loading search results
Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients
Sponsor study identifier
Secondary identifiers
observational
30
0 countries
N/A
Study Start
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Brain-derived neurotrophic factor (BDNF), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. Visceral hypersensitivity is recognized as a clinical hallmark in IBS patients. So in this study, the investigators will focus on the role of BDNF in colonic hyperalgesia in IBS patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
June 18, 2009
Actual (reported)June 22, 2009
Actual (reported)August 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
patients with diarrhea-predominant IBS will be enrolled in this group.
patients with colon cancer or colon polyp will be enrolled as control group.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel habits in the absence of structural and biochemical abnormalities.
two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.
Yanqing Li, PhD. MD.
Department of Gastroenterology, Qilu Hospital, Shandong University
First Submitted
June 18, 2009
First Posted
June 22, 2009
Study Start
June 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation
Contact the study team to confirm eligibility.
Study Completion
November 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 14, 2009
Record last verified: 2009-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: